Myriam Briki

EPFL STI IEM SCI-STI-SC
MC A3 154 (Bâtiment MC)
Rue de la Maladière 71b, CP 526
2002 Neuchâtel 2
+41 21 693 00 03
Office:
MC A3 154
EPFL
>
STI
>
IEM
>
SCI-STI-SC
Web site: Web site: https://www.epfl.ch/labs/bci/
Fields of expertise
- Pharmacometrics
- Therapeutic drug monitoring
- Analytical chemistry
Biography
Myriam Briki obtained her BSc from the University of Lausanne after spending her final year at Uppsala University (Sweden), where she was able to focus mainly on toxicological sciences. As a result, she chose to specialize in pharmacology and toxicology during her MSc back in Lausanne.She is now doing her PhD under the direction of Prof. Sandro Carrara (EPFL) and Dr. Monia Guidi (CHUV).
Her project, carried out at the University Hospital of Lausanne (Centre Hospitalier Universitaire Vaudois - CHUV), involves the development of population pharmacokinetic (pop-PK) meta-models for conventional cytotoxic chemotherapies. Once developed and validated, these models will make it possible to predict the evolution of the plasma concentration of the drugs for patients undergoing chemotherapy in order to adjust their dosage to achieve optimal therapeutic exposure, using maximum a posteriori Bayesian estimation in the context of therapeutic drug monitoring (TDM).
Along with her thesis work, she takes part in routine clinical tasks at the Service of Clinical Pharmacology (CHUV), interpreting TDM results for anticancer and antiretroviral therapies.
Education
MSc
Medical Biology Specialization in Pharmacology and Toxicology
University of Lausanne
2020-2022
BSc
Biology (3rd year of BSc)
Uppsala University
2019-2020
BSc
Biology
University of Lausanne
2017-2020
Publications
Selected publications
M. Briki, P. André, Y. Thoma, N. Widmer, A.D. Wagner, L.A. Decosterd, T. Buclin, M. Guidi, S. Carrara Pharmaceutics |
Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective |
M. Briki, A. Murisier, M. Guidi, C. Seydoux, T. Buclin, C. Marzolini, F.R. Girardin, Y. Thoma, S. Carrara, E. Choong, L.A. Decosterd Journal of Chromatography B |
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update |
C. Seydoux, M. Briki, A.D. Wagner, E. Choong, M. Guidi, S. Carrara, Y. Thoma, F. Livio, F.R. Girardin, C. Marzolini, T. Buclin, L.A. Decosterd Chemotherapy |
Importance of Sex-Dependent differences for dosing selection and optimization of chemotherapeutic drugs |
P. Ekobena, M. Briki, K. Dao, C. Marzolini, P. Andre, T. Buclin, M. Cavassini, M. Guidi, P. Thoueille Journal of Antimicrobial Chemotherapy |
Population pharmacokinetics of bictegravir in real-world people with HIV |
M. Pallanza, P. Thoueille, M. Briki, S. Alves Saldanha, M. Cavassini, C. Marzolini Antiviral therapy |
Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine |
T. Mercier, V. Desfontaine, S. Cruchon, J.A. Da Silva Pereira Clara, M. Briki, J. Mazza-Stalder, A. Kajkus, R. Burger, V. Suttels, T. Buclin, O. Opota, N. Koehler, P.M. Sanchez Carballo, C. Lange, P. Andre, L.A. Decosterd, E. Choong Journal of Chromatography B |
A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis |
J. Geurts, C. Wen, M. Briki, E. Moradpour, T. Hügle Bone Reports |
Optical clearing-based 3D-imaging of vascularization and mineralization of human degenerative osteochondral tissue |
O. Roessinger, M. Blanchard, M. Briki, D. Jurić, C. Netzer, T. Ecker, T. Hügle, J. Geurts Osteoarthritis and Cartilage |
Ex vivo biomarker profiling identifies oncostatin-M signaling as spine OA-specific target |